← All Urogen Pharma LTD filings

Urogen Pharma LTD 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
URGN
Urogen Pharma LTD
10-K: UroGen Pharma's 2025 Annual Report: Revenue Growth & Pipeline
UroGen Pharma's 2025 annual report details significant revenue growth driven by Jelmyto and Zusduri sales, alongside pipeline advancements and increased operating losses.
NASDAQ
URGN
Urogen Pharma LTD
10-K/A: UroGen Pharma Files Amendment No. 1 to 2024 Annual Report on Form 10-K/A
UroGen Pharma files an amendment to its 2024 annual report to include information required by Part III of Form 10-K, covering directors, executive officers, compensation, security ownership, related transactions, and accountant fees.
NASDAQ
URGN
Urogen Pharma LTD
10-K: UroGen Pharma Reports FY2024 Results, Highlights UGN-102 NDA Acceptance
UroGen Pharma details its financial performance for 2024 and provides updates on its key product pipeline, including the FDA's acceptance of the NDA for UGN-102.
NASDAQ
URGN
Urogen Pharma LTD
10-K/A: UroGen Pharma Files Amendment to 2023 Annual Report, Providing Additional Information on Directors, Executive Compensation and Governance
UroGen Pharma has filed an amendment to its 2023 annual report to include information required by Part III of Form 10-K, specifically detailing director and executive information, compensation, and governance.
NASDAQ
URGN
Urogen Pharma LTD
10-K: UroGen Pharma Amends Manufacturing Agreement, Files 10-K Highlighting Pipeline Progress
UroGen Pharma Ltd. amends its manufacturing and supply agreement with Cenexi-Laboratoires Thissen S.A. to prepare for increased production volumes and files its annual 10-K report, detailing financial results and pipeline advancements.